<--- Back to Details
First PageDocument Content
Monoclonal antibodies / Autoimmune diseases / Immunosuppressants / Biotechnology / RTT / Infliximab / Ulcerative colitis / Biopharmaceutical / Adalimumab / Inflammatory bowel disease / Ustekinumab / Biosimilar
Date: 2016-08-09 08:21:07
Monoclonal antibodies
Autoimmune diseases
Immunosuppressants
Biotechnology
RTT
Infliximab
Ulcerative colitis
Biopharmaceutical
Adalimumab
Inflammatory bowel disease
Ustekinumab
Biosimilar

www.medscape.com/viewarticle/864011_print www.medscape.com

Add to Reading List

Source URL: digestivehealthfoundation.org

Download Document from Source Website

File Size: 156,84 KB

Share Document on Facebook

Similar Documents

25SA16A ________________________________________________________________________________________________________ Glyphosate pathways to modern diseases VI: Prions, amyloidoses and autoimmune neurological diseases Anthony

DocID: 1voae - View Document

National Institute of Allergy and Infectious Diseases Awards MERS/SARS Coronavirus Drug Research Grant to Autoimmune Technologies FOR IMMEDIATE RELEASE New Orleans, June 24, Autoimmune Technologies LLC, a New Orle

DocID: 1uTGp - View Document

The Microbiome, which feeds a myriad of Autoimmune Diseases PRESENTED BY PROFESSOR TREVOR G MARSHALL Autoimmunity Research Foundation, CA, USA Murdoch University, Western Australia Autoimmunity Congress Granada, Spain, M

DocID: 1upLN - View Document

BioMed 258 Final Paper Eve Nakamura Autoimmune Cytopenias Autoimmune diseases are caused by a combination of genetic, epigenetic, and environmental factors and

DocID: 1u7zf - View Document

Medicine / Biology / Clinical medicine / Biotechnology / Immunology / ActoBiotics / Autoimmune diseases / Bacteriology / Biopharmaceutical / Immunogenicity / Mucositis / Human microbiota

Overview ActoBiotics® Platform: A Novel Class of Oral Biotherapeutics

DocID: 1rtnN - View Document